Note: Hospira's revenues are gauged from an analysis of company filings.
Hospira's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
Hospira Revenue (Sales)
Cost of Goods Sold
Salaries and wages
Other Operating Expenses
Total Operating Expenses
EBIT (Earnings Before Interest and Taxes)
Trademark applications show the products and services that Hospira is developing and marketing.
Hospira's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
VESTEME Pharmaceutical preparations for stimulating white blood cell production
VESTYM Pharmaceutical preparations for stimulating white blood cell production
FILVESTYM Pharmaceutical preparations for stimulating white blood cell production
Determine whether Hospira grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Hospira is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Hospira's Largest Competitors
A competitive analysis shows these companies are in the same general field as Hospira, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are in the same general field as Hospira and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.